
Rossari Biotech (ROSSARI) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Jun 2025Income Metrics
Revenue
5.4B
Gross Profit
1.7B
31.70%
Operating Income
501.1M
9.22%
Net Income
336.0M
6.18%
EPS (Diluted)
₹6.06
Balance Sheet Metrics
Total Assets
19.0B
Total Liabilities
7.1B
Shareholders Equity
11.9B
Debt to Equity
0.60
Cash Flow Metrics
Revenue & Profitability Trend
Rossari Biotech Income Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Revenue | 20.7B | 18.3B | 16.5B | 14.8B | 7.1B |
Cost of Goods Sold | 14.5B | 13.0B | 11.8B | 11.1B | 4.7B |
Gross Profit | 6.2B | 5.2B | 4.7B | 3.6B | 2.4B |
Gross Margin % | 30.0% | 28.6% | 28.6% | 24.5% | 34.3% |
Operating Expenses | |||||
Research & Development | - | - | - | - | - |
Selling, General & Administrative | 1.2B | 813.3M | 828.4M | 634.8M | 431.6M |
Other Operating Expenses | 846.5M | 693.6M | 601.9M | 395.3M | 188.3M |
Total Operating Expenses | 2.1B | 1.5B | 1.4B | 1.0B | 619.9M |
Operating Income | 1.9B | 1.8B | 1.5B | 1.3B | 1.0B |
Operating Margin % | 9.0% | 10.0% | 9.2% | 8.8% | 14.2% |
Non-Operating Items | |||||
Interest Income | 8.6M | 22.4M | 25.2M | 40.7M | 42.6M |
Interest Expense | 178.1M | 193.7M | 223.2M | 126.6M | 29.9M |
Other Non-Operating Income | - | - | - | - | - |
Pre-tax Income | 1.9B | 1.8B | 1.4B | 1.4B | 1.1B |
Income Tax | 488.1M | 469.3M | 369.6M | 385.8M | 267.9M |
Effective Tax Rate % | 26.4% | 26.4% | 25.6% | 28.3% | 25.1% |
Net Income | 1.4B | 1.3B | 1.1B | 977.0M | 800.5M |
Net Margin % | 6.6% | 7.2% | 6.5% | 6.6% | 11.3% |
Key Metrics | |||||
EBITDA | 2.7B | 2.5B | 2.3B | 2.0B | 1.3B |
EPS (Basic) | ₹24.66 | ₹23.67 | ₹19.46 | ₹17.81 | ₹15.56 |
EPS (Diluted) | ₹24.63 | ₹23.62 | ₹19.38 | ₹17.70 | ₹15.47 |
Basic Shares Outstanding | 55307858 | 55209962 | 55114297 | 54848162 | 51565168 |
Diluted Shares Outstanding | 55307858 | 55209962 | 55114297 | 54848162 | 51565168 |
Income Statement Trend
Rossari Biotech Balance Sheet From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 442.0M | 251.7M | 692.0M | 374.8M | 152.1M |
Short-term Investments | 722.6M | 416.2M | 793.0M | 269.5M | 731.5M |
Accounts Receivable | 4.7B | 4.3B | 3.5B | 3.0B | 1.4B |
Inventory | 3.6B | 2.8B | 1.9B | 1.9B | 953.5M |
Other Current Assets | 8.2M | 7.4M | 6.3M | 483.3M | 242.2M |
Total Current Assets | 10.4B | 8.4B | 7.2B | 6.1B | 3.5B |
Non-Current Assets | |||||
Property, Plant & Equipment | 0 | 3.1B | 3.1B | 442.0M | 69.4M |
Goodwill | 3.6B | 3.8B | 3.9B | 3.5B | 160.1M |
Intangible Assets | 1.3B | 1.4B | 1.6B | 1.7B | 107.6M |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | 30.0K | 30.0K | 30.0K | 710.0K | 1.1M |
Total Non-Current Assets | 8.5B | 7.3B | 6.5B | 6.5B | 2.1B |
Total Assets | 19.0B | 15.7B | 13.7B | 12.6B | 5.6B |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 2.9B | 2.2B | 1.8B | 1.9B | 1.3B |
Short-term Debt | 956.6M | 745.6M | 390.0M | 84.3M | 0 |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | 894.1M | 897.7M | 940.1M | 677.8M | 68.8M |
Total Current Liabilities | 5.4B | 4.2B | 3.5B | 2.9B | 1.5B |
Non-Current Liabilities | |||||
Long-term Debt | 1.2B | 442.3M | 349.3M | 0 | 0 |
Deferred Tax Liabilities | 465.7M | 514.7M | 587.2M | 689.5M | 12.9M |
Other Non-Current Liabilities | - | - | 73.9M | 850.3M | - |
Total Non-Current Liabilities | 1.7B | 996.9M | 1.0B | 1.6B | 23.9M |
Total Liabilities | 7.1B | 5.2B | 4.5B | 4.5B | 1.5B |
Equity | |||||
Common Stock | 110.7M | 110.5M | 110.3M | 110.1M | 103.9M |
Retained Earnings | 7.0B | 5.6B | 4.4B | 3.3B | 2.4B |
Treasury Stock | - | - | - | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 11.9B | 10.5B | 9.2B | 8.1B | 4.1B |
Key Metrics | |||||
Total Debt | 2.2B | 1.2B | 739.3M | 84.3M | 0 |
Working Capital | 5.1B | 4.2B | 3.7B | 3.1B | 2.0B |
Balance Sheet Composition
Rossari Biotech Cash Flow Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | 1.9B | 1.8B | 1.4B | 1.4B | 1.1B |
Depreciation & Amortization | - | - | - | - | - |
Stock-Based Compensation | 680.0K | 6.9M | 9.4M | 18.3M | 16.3M |
Working Capital Changes | -1.6B | -2.1B | -278.7M | -907.1M | -724.8M |
Operating Cash Flow | 440.1M | -114.2M | 1.4B | 550.4M | 347.2M |
Investing Activities | |||||
Capital Expenditures | -1.6B | -1.3B | -311.9M | -363.1M | -559.0M |
Acquisitions | -3.2M | -177.3M | -985.3M | -3.6B | -43.4M |
Investment Purchases | - | - | - | - | - |
Investment Sales | - | - | - | 15.5M | 137.2M |
Investing Cash Flow | -1.6B | -1.4B | -1.3B | -3.0B | -407.1M |
Financing Activities | |||||
Share Repurchases | - | - | - | - | - |
Dividends Paid | -27.6M | -27.6M | -27.5M | -27.5M | -25.4M |
Debt Issuance | 934.8M | 0 | 449.2M | 0 | 0 |
Debt Repayment | -385.8M | -115.8M | 0 | -48.1M | -610.1M |
Financing Cash Flow | 844.5M | 329.9M | 669.6M | 2.9B | -477.5M |
Free Cash Flow | -210.7M | -880.3M | 1.2B | -88.7M | -103.2M |
Net Change in Cash | -303.5M | -1.2B | 728.6M | 403.2M | -537.4M |
Cash Flow Trend
Rossari Biotech Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
26.15
Forward P/E
19.00
Price to Book
2.98
Price to Sales
1.65
PEG Ratio
19.00
Profitability Ratios
Profit Margin
6.33%
Operating Margin
9.22%
Return on Equity
11.50%
Return on Assets
7.19%
Financial Health
Current Ratio
1.94
Debt to Equity
18.39
Beta
0.27
Per Share Data
EPS (TTM)
₹24.37
Book Value per Share
₹214.12
Revenue per Share
₹385.68
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
rossari | 35.3B | 26.15 | 2.98 | 11.50% | 6.33% | 18.39 |
Asian Paints | 2.4T | 65.80 | 12.24 | 18.28% | 10.63% | 11.42 |
Pidilite Industries | 1.6T | 71.77 | 16.03 | 20.85% | 16.16% | 4.56 |
Balaji Amines | 49.7B | 32.59 | 2.69 | 7.80% | 11.11% | 0.55 |
Camlin Fine Sciences | 44.0B | 81.82 | 4.88 | 5.71% | -8.34% | 77.88 |
Grauer & Weil | 43.7B | 27.77 | 4.65 | 18.02% | 13.85% | 1.26 |
Financial data is updated regularly. All figures are in the company's reporting currency.